Nevertheless, 0.9–1.3% of CSF-TPRs of lapatinib were observed in two adult female patients diagnosed with HER2-positive (one HR-negative and one HR-positive) ductal carcinoma yielding CNS metastases. Here, ERBB2 is linked to breast ductal adenocarcinoma.